Results 1 to 2 of 2

Thread: Human Genome Sciences And Lonza Enter Commercial Manufacturing Agreement For BENLYSTA

  1. #1
    Join Date
    Nov 2009
    Posts
    150
    Thanks
    0
    Thanked 20 Times in 13 Posts

    Default Human Genome Sciences And Lonza Enter Commercial Manufacturing Agreement For BENLYSTA

    Human Genome Sciences, Inc. (Nasdaq:HGSI) and Lonza announced an agreement for the future commercial supply of BENLYSTAŽ (belimumab), which is currently under regulatory review in the United States and Europe as a potential new treatment for systemic lupus erythematosus (SLE)...

    More...

  2. #2
    Saysusie's Avatar
    Saysusie is offline Super Moderator Super ModeratorEmperor of the Universe
    Join Date
    Nov 2001
    Location
    Victorville, California
    Posts
    7,721
    Blog Entries
    9
    Thanks
    1,578
    Thanked 919 Times in 582 Posts

    Default

    In lupus and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies - antibodies that attack and destroy the body's own healthy tissues. The presence of autoantibodies appears to correlate with disease severity. Preclinical and clinical studies demonstrated that belimumab reduced autoantibody levels in SLE. The results of two pivotal Phase 3 trials, BLISS-52 and BLISS-76, demonstrated that belimumab reduced SLE disease activity.
    Look For The Good and Praise It!

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •